Valuation: Pacific Biosciences of California, Inc.

Market Cap 435M 378M 352M 323M 610M 41.51B 619M 4.15B 1.63B 20.67B 1.63B 1.6B 69.3B P/E 2026 *
-3.37x
P/E 2027 * -2.96x
Enterprise Value 435M 378M 352M 323M 610M 41.51B 619M 4.15B 1.63B 20.67B 1.63B 1.6B 69.3B EV / Sales 2026 *
2.6x
EV / Sales 2027 * 2.24x
Free-Float
91.23%
Yield 2026 *
-
Yield 2027 * -
1 week+3.26%
1 month-17.44%
3 months-9.03%
6 months-35.22%
Current year-17.50%
1 week 1.18
Extreme 1.1825
1.27
1 month 1.17
Extreme 1.1685
1.57
3 years 0.75
Extreme 0.7537
12.18
Manager TitleAgeSince
Chief Executive Officer 58 14/09/2020
Director of Finance/CFO 57 31/03/2025
Chief Operating Officer 53 08/01/2021
Director TitleAgeSince
Director/Board Member 67 01/01/2004
Director/Board Member 72 01/01/2009
Director/Board Member 69 18/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
-2.59%+3.26%+1.41%-89.79% 435M
-0.43%+1.06%+24.03%+5.21% 212B
-0.61%+1.82%-1.07%-23.54% 137B
+0.10%+4.69%-26.86%+9.07% 125B
+1.59%+5.60%-55.67%-9.94% 69.46B
-0.98%+4.16%+8.50%+4.90% 49.56B
-0.91%+5.13%-20.61%-29.50% 47.2B
-0.25%-0.14%+21.91%+12.97% 39.08B
-0.79%+0.70%+29.97%+37.50% 37.05B
+0.00%+5.67%+116.67%+8.35% 30.97B
Average -0.25%+3.14%+9.83%-7.48% 83.06B
Weighted average by Cap. -0.24%+2.77%+3.70%-0.95%

Financials

2026 *2027 *
Net sales 167M 146M 135M 124M 235M 15.98B 239M 1.6B 627M 7.96B 629M 615M 26.68B 194M 169M 157M 144M 273M 18.55B 277M 1.85B 727M 9.23B 730M 714M 30.96B
Net income -131M -114M -106M -97.21M -184M -12.49B -186M -1.25B -490M -6.22B -491M -481M -20.85B -153M -133M -123M -113M -214M -14.56B -217M -1.46B -571M -7.25B -573M -560M -24.31B
Net Debt - -
Logo Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. It focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.
Employees
-
Date Price Change
31/07/26 €1.221 -2.59%
30/07/26 €1.254 +1.87%
29/07/26 €1.231 +0.90%
28/07/26 €1.220 +1.54%
27/07/26 €1.201 +1.56%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.400USD
Average target price
2.458USD
Spread / Average Target
+75.60%

Quarterly revenue - Rate of surprise